Note: Descriptions are shown in the official language in which they were submitted.
CA 02747802 2011-06-20
WO 2010/075239 PCT/US2009/068888
- 1 -
Dosage Regimen for a S1P Receptor Agonist
The present invention relates to a dosage regimen of a SIP receptor modulator
or agonist.
More specifically, the present invention relates to a dosage regimen for the
treatment of
patients suffering from autoimmune diseases or disorders, such as, for
example, multiple
sclerosis with a SIP receptor modulator or agonist.
SIP receptor modulators or agonists are compounds which signal as agonists at
one or
more sphingosine-1 phosphate receptors, for example, S1P1 to S1 P8. The
binding of an
agonist to a S1P receptor may, for example, result in the dissociation of
intracellular
heterotrimeric G-proteins into Gá-GTP and Gaa-GTP, and/or the increased
phosphorylation
of the agonist-occupied receptor, and/or the activation of downstream
signaling
pathways/kinases.
S1P receptor modulators or agonists are useful therapeutic compounds for the
treatment of
various conditions in mammals, especially in human beings. For example, the
efficacy of
S1P receptor modulators or agonists in the prevention of transplant rejection
has been
demonstrated in rat (skin, heart, liver, small bowel), dog (kidney), and
monkey (kidney)
models. In addition, due to their immune-modulating potency, SIP receptor
modulators or
agonists are also useful for the treatment of inflammatory and autoimmune
diseases. In
particular, the efficacy of the S1P receptor agonist FTY720 in the treatment
of multiple
sclerosis has been demonstrated in humans (as described in, for example,
"FTY720 therapy
exerts differential effects on T cell subsets in multiple sclerosis". Mehling
M, Brinkmann V,
Ante! J, Bar-Or A, Goebels N, Vedrine C, Kristofic C, Kuhle J, Lindberg RL,
Kappos L.
Neurology. 2008 Oct 14;71(16)1261-7; and "Oral fingolimod (FTY720) for
relapsing multiple
sclerosis". Kappos L, Ante! J, Comi G, Montalban X, O'Connor P, Po!man CH,
Haas T, Korn
AA, Karlsson G, Radue EW; FTY720 D2201 Study Group. N Engl J Med. 2006 Sep
14;355(11)1124-40.).
Multiple sclerosis is the chief cause of neurological disability in young
adults and the most
common demyelinating disorder of the central nervous system. Currently
available therapies,
such as interferon-a and glatiramer acetate, only have modest efficacy and
therefore
demonstrate only marginal effects on the progression of the disease.
Furthermore,
these biological agents are administered parenterally and are associated with
some adverse
effects such as, for example, localized reactions at the injection site and
pyretic symptoms.
Therefore, there is a strong medical need for an effective oral treatment for
multiple
sclerosis.
CA 02747802 2011-06-20
WO 2010/075239 PCT/US2009/068888
- 2 -
S1P receptor modulators or agonists may produce a negative chronotropic
effect, i.e. they
may reduce the cardiac rhythm, as described e.g. in '`FTY720: Placebo-
Controlled Study of
the Effect on Cardiac Rate and Rhythm in Healthy Subjects", Robert Schmouder,
Denise
Serra, Yibin Wang, John M. Kovarik, John DiMarco, Thomas L Hunt and Marie-
Claude
Bastien. J. Clin. Pharmacol. 2006; 46; 895. Administration of 1.25 mg of
FTY720 may induce
a decrease in heart rate of approximately 8 beats/min (BPM).
As a consequence of this side effect, the S1P modulator or agonist therapy may
have to be
initiated under close medical supervision in order to check that the cardiac
rhythm is
maintained at an acceptable level. This may involve the hospitalisation of
patients, which
makes the treatment more expensive and complicated.
Therefore, there is a need to reduce the negative chronotropic side effect
that may be
generated by the administration of SIP receptor modulators or agonists, while
maintaining
the ability to administer an adequate dosage in order to treat or prevent the
diseases for
which the compound is administered. There is furthermore a need to enhance
patient
compliance.
Brief Disclosure of the Invention
Surprisingly it has been found that by administering the SIP receptor
modulator or agonist
according to a specific dosage regimen, it is possible to reduce side effects
which may be
associated with the administration of such compounds. For example,
administering a S1P
receptor agonist or modulator according to the specific dosage regimen of the
present
invention may significantly, reduce or even completely eliminate, the negative
chronotropic
side effect. In particular it may avoid an abrupt drop in the heart rate.
Administering a SIP receptor agonist or modulator according to the specific
dosage regimen
of the present invention may also significantly reduce or even completely
eliminate the risks
that the patients taken the S1P receptor agonist or modulator suffer from
atrio-ventricular
(AV) blocks or heart pause.
Furthermore the specific dosage regimen of the present invention permits to
administer a
S1P receptor agonist or modulator to categories of patients for which the
ratio risk/benefit
may otherwise be less favourable. Such patients are for example patients
susceptible to or
suffering from heart failure or arrythmias, patients with high grade atrio-
ventricular blocks or
sick sinus syndrome, patients with a history of syncopal episodes, or patients
under beta
blockers or anti-arrhythmic treatment, such as patients under anti-arrhythmic
drugs; or
81538746
- 3 -
patients that have undergone an interruption or treatment holiday in the
maintenance
dosage regime e.g. a holiday of greater than 4 days, greater than 6,8, 10, 12
or 14 days.
The dosage regimen of the present invention is a regimen for the initiation of
S1P receptor
modulator or agonist therapy, which enables the standard daily therapeutic
dosage range
of the SIP receptor to be achieved with minimal negative chronotropic effects
and/or the
AV block effects possibly associated with SIP receptor modulator therapy.
In another embodiment, there is provided the SIP receptor modulator or agonist
2-amino-
242-(4-octylphenypethyl]propane-1,3-diol in free form or in a pharmaceutically
acceptable
salt form for use in treatment of multiple sclerosis in a patient, wherein the
SIP receptor
modulator or agonist is for administration at a daily dosage of less than
about 0.5mg.
According to one aspect of the present invention, there is provided use of a
SIP receptor
modulator or agonist for the treatment of an autoimmune disease, wherein the
autoimmune disease is selected from the list consisting of multiple sclerosis,
polymyositis, lupus nephritis, rheumatoid arthritis, inflammatory bowel
disease and
psoriasis, wherein the daily dosage of the SIP receptor modulator or agonist
is (a) a first
initial dosage for a first initial treatment period of four days, (b) a second
initial dosage for
a second initial treatment period of three days following the first initial
treatment period,
and (c) a standard daily therapeutic dosage following the second initial
treatment period,
wherein the first initial dosage is 54-fold less than the standard daily
therapeutic dosage
and the second initial dosage is 2.5-fold less than the standard daily
therapeutic dosage.
According to another aspect of the present invention, there is provided use of
a S1P
receptor modulator or agonist for the prevention or amelioration of a negative
chronotropic side effect associated with a treatment using an S1P modulator or
agonist
of a subject suffering from an autoimmune disease, wherein said prevention or
amelioration of a negative chronotropic side effect comprises use of a daily
dosage of the
SIP receptor modulator or agonist which is (a) a first initial dosage for a
first initial
treatment period of four days, (b) a second initial dosage for a second
initial treatment
period of three days following the first initial treatment period, and (c) a
standard daily
Date Recue/Date Received 2020-04-17
81538746
- 3a -
therapeutic dosage following the second initial treatment period, wherein the
first initial
dosage is 54-fold less than the standard daily therapeutic dosage and the
second initial
dosage is 2.5-fold less than the standard daily therapeutic dosage.
According to another aspect of the present invention, there is provided use of
a S1P
receptor modulator or agonist for the treatment of an autoimmune disease,
wherein the
autoimmune disease is selected from the list consisting of multiple sclerosis,
polymyositis, lupus nephritis, rheumatoid arthritis, inflammatory bowel
disease and
psoriasis, wherein the daily dosage of the S1P receptor modulator or agonist
is (a) an
initial dosage for an initial treatment period of four days, and (b) a
standard daily
therapeutic dosage following the initial treatment period, wherein the initial
dosage is 2-
fold less than the standard daily therapeutic dosage.
According to another aspect of the present invention, there is provided use of
a S1P
receptor modulator or agonist for the prevention or amelioration of a negative
chronotropic side effect associated with a treatment using an SIP modulator or
agonist
of a subject suffering from an autoimmune disease, wherein said prevention or
amelioration of a negative chronotropic side effect comprises use of a daily
dosage of the
SIP receptor modulator or agonist which is (a) an initial dosage for an
initial treatment
period of four days, and (b) a standard daily therapeutic dosage following the
initial
treatment period, wherein the initial dosage is 2-fold less than the standard
daily
therapeutic dosage.
According to another aspect of the present invention, there is provided use of
a S1P
receptor modulator or agonist for the treatment of an autoimmune disease,
wherein the
autoimmune disease is selected from the list consisting of multiple sclerosis,
polymyositis, lupus nephritis, rheumatoid arthritis, inflammatory bowel
disease and
psoriasis, wherein the daily dosage of the SIP receptor modulator or agonist
is (a) 0.25
mg for a first initial treatment period of four days, (b) 0.5 mg for a second
initial treatment
period of three days following the first initial treatment period, and (c)
1.25 mg following
the second treatment period.
Date Recue/Date Received 2020-04-17
81538746
- 3b -
According to another aspect of the present invention, there is provided use of
a S1P
receptor modulator or agonist for the prevention or amelioration of a negative
chronotropic side effect associated with a treatment using an SIP modulator or
agonist
of a subject suffering from an autoimmune disease, and wherein said prevention
or
amelioration of a negative chronotropic side effect comprises use of a daily
dosage of the
SIP receptor modulator or agonist is (a) 0.25 mg for a first initial treatment
period of four
days, (b) 0.5 mg for a second initial treatment period of three days following
the first initial
treatment period, and (c) 1.25 mg following the second treatment period.
According to still another aspect of the present invention, there is provided
use of a SIP
receptor modulator or agonist for the treatment of an autoimmune disease,
wherein the
autoimmune disease is selected from the list consisting of multiple sclerosis,
polymyositis, lupus nephritis, rheumatoid arthritis, inflammatory bowel
disease and
psoriasis, wherein the daily dosage of the SIP receptor modulator or agonist
is (a) 0.25
mg for an initial treatment period of four days, and (b) 0.5 mg following the
initial
treatment period.
According to yet another aspect of the present invention, there is provided
use of a S1P
receptor modulator or agonist for the prevention or amelioration of a negative
chronotropic side effect associated with a treatment using an SIP modulator or
agonist
of a subject suffering from an autoimmune disease, and wherein said prevention
or
amelioration of a negative chronotropic side effect comprises use of a daily
dosage of the
SIP receptor modulator or agonist is (a) 0.25 mg for an initial treatment
period of four
days, and (b) 0.5 mg following the initial treatment period.
SIP receptor modulators or agonists
Preferred SIP receptor agonists or modulators are, for example, compounds
which, in
addition to their SIP binding properties, also have accelerating lymphocyte
homing
properties. For example, the compounds may elicit lymphopenia resulting from a
re-
distribution of lymphocytes from the circulation to the secondary lymphatic
tissue, which
is preferably reversible, without evoking a generalized immunosuppression.
Suitably,
Date Recue/Date Received 2020-04-17
81538746
- 3c -
naïve cells are sequestered and CD4 and CD8 T-cells and B-cells from the blood
are
stimulated to migrate into lymph nodes (LN) and Peyer's patches (PP).
SIP receptor modulators or agonists are typically sphingosine analogues, such
as 2-
substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives.
In an embodiment of the invention, the SIP receptor modulator or agonist is a
compound
comprising a group of formula X
RuiR2,N __________________ -CH2R1z (X)
Date Recue/Date Received 2020-04-17
CA 02747802 2011-06-20
WO 2010/075239
PCT/US2009/068888
- 4 -
Riz is OH, acyloxy or a residue of formula (a); and each of R2z and R3,
independently, is H,
Ci_olkyl or acyl.
The group of formula X is a functional group which is attached as a terminal
group to a
moiety which may be hydrophilic or lipophilic and comprise one or more
aliphatic, alicyclic,
aromatic and/or heterocyclic residues. The resultant molecule functions as a
modulator/agonist at one of more sphingosine-1-phosphate receptors.
Suitably, at least one of Z and R1, is or comprises a residue of formula (a).
Examples of appropriate Si P receptor agonists or modulators include:
(i) Compounds as disclosed in EP627406A1, e.g. a compound of formula I
CH2OR3
R4R3N ________________________ CH2OR2
R1
wherein R1 is a straight- or branched (C1222)chain
- which may have in the chain a bond or a hetero atom selected from a
double bond, a
triple bond, 0, S, NR6, wherein R6 is H, C1_4alkyl, aryl-C1_4alkyl, acyl or
(C1_
4a1koxy)carbonyl, and carbonyl, and/or
- which may have as a substituent C14alkoxy, C2_4alkenyloxy, C24alkynyloxy,
aryIC1
4a1ky1-oxy, acyl, C1alkylamino, C1alkylthio, acylamino, (Ci_olkoxy)carbonyl,
(C1_
4a1koxy)-carbonylamino, acyloxy, (Calkyl)carbamoyl, nitro, halogen, amino,
hydroxyimino, hydroxy or carboxy; or
R1 is
- a phenylalkyl wherein alkyl is a straight- or branched (C20)carbon chain;
or
- a phenylalkyl wherein alkyl is a straight- or branched (01_30)carbon chain
wherein said
phenylalkyl is substituted by
- a straight- or branched (C620)carbon chain optionally substituted by
halogen,
- a straight- or branched (C6_20)alkoxy chain optionally substitued by
halogen,
- a straight- or branched (C6_20)alkenyloxy,
- phenyl-C1_14alkoxy, halophenyl-Ci_olkoxy, phenyl-Ci_ualkoxy-Ci_ualkyl,
phenoxy-C1..4alkoxy or phenoxy-C-malkyl,
- cycloalkylaikyl substituted by C6_2Dalkyl,
- heteroaryialkyl substituted by C6_20alkyl,
- heterocyclic C6_20alkyl or
- heterocyclic alkyl substituted by C2_20alkyl,
and wherein the alkyl moiety may have:
CA 02747802 2011-06-20
WO 2010/075239 PCT/US2009/068888
-5-
- in the carbon chain, a bond or a heteroatom selected from a double bond,
a triple
bond, 0, S. sulfinyl, sulfonyl, or NR6, wherein R6 is as defined above, and
- as a substituent C1_4alkoxy, C2_4alkenyloxy, C2_4alkynyloxy,
arylCi_olkyloxy, acyl,
Ci_ 4a1ky1-amino, C1alkyIthio, acylamino, (Ci_olkoxy)carbonyl, (C1-
4alkoxy)carbonylamino, acyloxy, (Ci_olkyl)carbamoyl, nitro, halogen, amino,
hydroxy
or carboxy; and
each of R2, R3, R4 and R5, independently, is H, C1_4 alkyl or acyl
or a pharmaceutically acceptable salt or hydrate thereof.
(ii)Compounds as disclosed in W002/18395, e.g. a compound of formula ha or lib
CH R
CH2R3a 2 3b Ria
Rla
(R2a ) 2N-IC-CH2 -X P
(R202N-1C-CH2-Xa _________ P =0
CH2 Rib CH2 R11,
CH2 or CH2
1.1 101
(CH2)7CH3 Ya-R4a
la Ilb
wherein X, is 0, S, NRis or a group ¨(CH2)n,-, which group is unsubstituted or
substituted by
1 to 4 halogen; na is 1 or 2, R-is is or (C1)alkyl, which alkyl is
unsubstituted or substituted
by halogen; Ria is H, OH, (C14)alkyl or 0(C14)alkyl wherein alkyl is
unsubstituted or
substituted by 1 to 3 halogen; Rib is H, OH or (C1_4)alkyl, wherein alkyl is
unsubstituted or
substituted by halogen; each R2, is independently selected from H or
(C1_4)alkyl, which alkyl
is unsubstituted or substitued by halogen; R3a is H, OH, halogen or
0(C1_4)alkyl wherein alkyl
is unsubstituted or substituted by halogen; and R3b is H, OH, halogen,
(C1_4)a1ky1 wherein
alkyl is unsubstituted or substituted by hydroxy, or 0(C14)alkyl wherein alkyl
is unsubstituted
or substituted by halogen; Y, is ¨CH2-, -C(0)-, -CH(OH)-, -C(=NOH)-, 0 or S,
and Ria is
(C414)alkyl or (C4-14)alkenyl;
or a pharmaceutically acceptable salt or hydrate thereof.
CA 02747802 2011-06-20
WO 2010/075239 PCT/US2009/068888
- 6 -
When the compounds of formulae I or ha or lib have one or more asymmetric
centers in the
molecule, the present invention is to be understood as embracing the various
optical
isomers, as well as racemates, diastereoisomers and mixtures thereof are
embraced.
Compounds of formula ha or lib, when the carbon atom bearing the amino group
is
asymmetric, have preferably the R-configuration at this carbon atom.
The compounds of formulae I, I la or Ilb may exist in free or salt form.
Examples of
pharmaceutically acceptable salts of the compounds of the formulae I, Ila or
lib include salts
with inorganic acids, such as hydrochloride, hydrobromide and sulfate, salts
with organic
acids, such as acetate, fumarate, maleate, benzoate, citrate, malate,
methanesulfonate and
benzenesulfonate salts, or, when appropriate, salts with metals such as
sodium, potassium,
calcium and aluminium, salts with amines, such as triethylamine and salts with
dibasic amino
acids, such as lysine. The compounds and salts of the combination of the
present invention
encompass hydrate and solvate forms.
In the above definitions:
= acyl may be a residue Ry-00- wherein Ry is C1_6alkyl, Cmcycloalkyl,
phenyl or
phenyl-Ci_olkyl
= unless otherwise stated, alkyl, alkoxy, alkenyl or alkynyl may be
straight or branched;
= aryl may be phenyl or naphthyl, preferably phenyl;
= "heterocyclic group" represents a 5- to 7 membered heterocyclic group
having 1 to 3
heteroatonns selected from S, 0 and N. Examples of such heterocyclic groups
include the heteroaryl groups indicated above, and heterocyclic compounds
corresponding to partially or completely hydrogenated heteroaryl groups, e.g.
furyl,
thienyl, pyrrolyl, azepinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl,
thiazolyi,
isothiazolyl, 1,2,3-oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyranyl,
pyridyl,
pyridazinyl, pyrimidinyl, pyrazinyl, tetrahydropyranyl, morpholinyl,
thiomorpholinyl,
pyrrolidinyl, pyrrolyl, imidazolidinyl, pyrazolidinyl, piperidinyl,
piperazinyl, oxazolidinyl,
isoxazolidinyl, thiazolidinyl or pyrazolidinyl. Preferred heterocyclic groups
are 5-or 6-
membered heteroaryl groups and the most preferred heteocyclic group is a
morpholinyl, thionnorpholinyl or piperidinyl group.
When the carbon chain as Ri is substituted in the compounds of formula I, it
is preferably
substituted by halogen, nitro, amino, hydroxy or carboxy. When the carbon
chain is
interrupted by an optionally substituted phenylene, the carbon chain is
preferably
unsubstituted. When the phenylene moiety is substituted, it is preferably
substituted by
halogen, nitro, amino, methoxy, hydroxy or carboxy.
CA 02747802 2011-06-20
WO 2010/075239 PCT/US2009/068888
- 7 -
Preferred compounds of formula I are those wherein Ri is C13_20alkyl,
optionally substituted
by nitro, halogen, amino, hydroxy or carboxy, and, more preferably those
wherein Ri is
phenylalkyl substituted by C6_14-alkyl chain optionally substituted by halogen
and the alkyl
moiety is a Ci_salkyl optionally substituted by hydroxy. More preferably, Ri
is phenyl-C1_6alkyl
substituted on the phenyl by a straight or branched, preferably straight,
C6_14alkyl chain. The
C6.14alkyl chain may be in ortho, meta or para, preferably in para.
Preferably each of R2 to R5 is H.
A preferred compound of formula I is 2-amino-2-tetradecy1-1,3-propanediol.
A particularly preferred S1P receptor agonist of formula I is FTY720, i.e. 2-
amino-2-[2-(4-
octylphenyl) ethyl]propane-1,3-diol in free form or in a pharmaceutically
acceptable salt form
(referred to hereinafter as Compound A), or a prodrug thereof.
In an embodiment of the invention, the agonist of formula I is FTY720
hydrochloride, as
shown below:
HO- ?H
H2N ___________________ I
= HCI
A preferred compound of formula Ila is the FTY720-phosphate (Compound B) (R2,
is H, R3,
is OH, X, is 0, Ria and Rib are OH).
A preferred compound of formula 1lb is the Compound C-phosphate (R2, is H, R3b
is OH, X,
IS 0, Ria and Rib are OH, Y, is 0 and R4a is heptyl).
In a further embodiment of the invention, a SIP receptor agonist or modulator
for use in the
dosage regimen of the invention may also be selective for the S1P1 receptor.
For example,
a compound which possesses selectivity for the Si P1 receptor over the Si P3
receptor of at
least 20 fold, e.g. 100, 500, 1000 or 2000 fold, as measured by the ratio of
EC50 for the S1P1
receptor to the EC50 for the Si P3 receptor as measured by a 35S-GTP7S binding
assay, and
wherein said compound has an ECK, for binding to the Si P1 receptor of 100 nM
or less as
evaluated by the 35S-GTPyS binding assay.
The 355-GTPyS binding assay is described in W003/097028 and follows the
following
protocol:
GTPyS binding experiments are performed as described by DS. Inn et al., Md.
Pharmacol.
2000; 57:753. Ligand-mediated GTP?S binding to G-proteins is measured in GTP
binding
CA 02747802 2011-06-20
WO 2010/075239 PCT/US2009/068888
- 8 -
buffer (in mM: 50 HEPES, 100 NaCI, 10 MgCl2, pH 7.5) using 25IJg of a membrane
preparation from transiently transfectecl HEK293 cells. Ligand is added to
membranes in the
presence of 10 pM GDP and 0.1 nM [35S1GTPyS (1200 Ci/mmol) and incubated at 30
C for
30 min. Bound GTP7S is separated from unbound using the Brandel harvester
(Gaithersburg, MD) and counted with a liquid scintillation counter.
Dosage Regimen
As previously stated, the present invention provides a novel dosage regimen
which is
adapted to minimize the negative chronotropic effects and/or the AV block
effects possibly
associated with SIP receptor modulator or agonist therapy.
Heart effects include AV blocks, which include first degree AV blocks (e.g. PR
intervals
greater then 0.2 seconds) and second degree AV blocks e.g. first degree AV
blocks_ Heart
effects include heart pauses e.g. heart pauses greater than 2 seconds.
According to the invention, there is provided the use of a SIP receptor
modulator or agonist
in the manufacture of a medication, whereby said medication is administered in
such a way
that during the initial period of treatment the dosage is lower than the
standard daily dosage
and the dosage is increased, optionally stepwise, or only once, until the
standard daily
dosage dose is reached. Thereafter the treatment is preferably continued with
the standard
daily dosage of said SI P receptor modulator or agonist.
Preferably during the initial period of treatment, the medication is
administered in a dosage
regimen such that daily decrease in heart rate (e.g. average or minimum daily
heart rate) is
acceptable or clinically not significant, or that the sinus rhythm of the
patient is normal. For
example, the daily decrease in heart rate (e.g. average or minimum daily heart
rate) may be
less than about 4bpm, e.g. less than about 3 bpm or less than about 2bpm.
The term "normal sinus rhythm" refers to the sinus rhythm of the patient when
not
undergoing treatment. The evaluation of normal sinus rhythm is within the
ability of a
physician. A normal sinus rhythm will generally give rise to a heart rate in
the range from 60-
100 bpm.
Preferably, during the initial period of treatment the dosage is lower than
the standard daily
dosage and the dosage is increased, optionally stepwise, or only once, until
the standard
daily dosage dose is reached. Thereafter the treatment is preferably continued
with the
standard daily dosage of said SIP receptor modulator or agonist.
According to the invention, the "initial period of treatment" refers to the
period during which
the SIP receptor modulator or agonist is administered at a dosage lower than
the standard
CA 02747802 2011-06-20
WO 2010/075239 PCT/US2009/068888
- 9 -
daily dosage. Preferably the "initial period of treatment" starts with the
first administration of
the S1P receptor modulator or agonist.
The duration of the initial period of treatment may vary. In an embodiment,
the initial period
of treatment is up to 10 days, e.g. about a week. In a further embodiment, the
initial period of
treatment is 5 to 14 days, e.g. 4 to 12 days. In a further embodiment, the
initial period of
treatment is 7 to 10 days. In yet a further embodiment, the initial period of
treatment is 4 to 7
days. In further embodiments, the initial period of treatment is selected from
10 days, or 9
days, or 8 days, or 7 days, or 6 days, or 5 days, or 4 days.
As herein above defined, standard daily dosage (also called standard daily
dose) refers to
the required daily maintenance dose of the drug which is given to the patients
for treating or
preventing the disease to be treated or prevented. Suitably, the standard
daily dosage
corresponds to the therapeutically effective dosage.
The therapeutically effective dosage (also called therapeutic dose) refers to
the dosage of
the S1P receptor modulator or agonist which is necessary to effectively treat
the intended
disease or condition (i.e. so that the subject shows reduced signs or symptoms
of rebound of
the disease to be treated or prevented, and preferably no signs and symptoms
at all).
During the initial period of treatment the S1P receptor modulator or agonist
may be
administered at a dosage e.g. up to 10-fold less, e.g. up to 8-fold less, e.g.
up to 4-fold less,
than the standard daily maintenance dose, e.g. than the therapeutic dose.
In a preferred embodiment, there is provided the use of an S1P receptor
modulator or
agonist in the manufacture of a medication, whereby said medication is
administered in such
a way that during the initial period of treatment (e.g. the first 10 days of
treatment, e.g. the
first week of treatment, or the first 5 to 14 days of treatment, the first 4
to 12 days of
treatment, or the first 7 to 10 days of treatment, or the first 10, 9, 8, 7, 6
, 5 or 4 days of
treatment), the dosage of said S1P receptor modulator or agonist is given at a
dosage of up
to 10-fold less, e.g. up to 5-fold less, than the standard daily dose, e.g.
the therapeutic dose.
Optionally the dose is then raised stepwise up to the standard daily dose,
e.g. the
therapeutic dose, during the initial period of treatment as herein above
defined.
Preferred medications comprise medication for patients suffering from chronic
long term
diseases, such as autoimmune diseases, e.g. multiple sclerosis, Polymyositis,
lupus
nephritis, rheumatoid arthritis, inflammatory bowel diseases or psoriasis. In
an embodiment
of the invention, medications are medications for patients suffering from
multiple sclerosis,
for example relapse remitting multiple sclerosis (RRMS) or primary progressive
multiple
sclerosis (PPMS), e.g. for patients suffering from RRMS.
CA 02747802 2011-06-20
WO 2010/075239 PCT/US2009/068888
- 10 -
The dosage regimen of the present invention is particularly useful for
treating patents at risk
of cardiac side effects, for example patients at risk of heart failure,
arrythmias, patients with
high grade atrio-ventricular blocks or sick sinus syndrome, patients with a
history of syncopal
episodes, or patients requiring or under beta blockers, or patients requiring
or under anti-
arrhythmic treatment, such as patients under treatment with Class la (e.g.
quinidine,
procainamide) or Class III anti-arrhythmic drugs (e.g., amiodarone, sotalol).
For compound A (or B), an example of standard daily dosage may be a daily
dosage of up to
5mg, for example, the dosage may be between 0.5 and 5 mg, e.g. between 0.5 and
2mg. In
a specific embodiment, the standard daily dosage is about 1.25 mg. In another
embodiment,
the standard daily dosage is about 0.5 mg.
Preferably, the dosage of the SIP receptor modulator or agonist during the
initial period of
treatment is increased stepwise in defined increments up to the standard daily
dosage of the
SIP receptor modulator or agonist. Preferably, the dosage of said SIP receptor
modulator
or agonist during the initial period of treatment as hereinabove defined, e.g.
during the initial
days, e.g. 1 to 9 days, e.g. first week of treatment is increased in
increments of about
1.5- to about 3.5-fold, for example from 2 to 3-fold, for example 2-fold, for
example about
1.5-fold.
For example, during the initial period, the dose may be about 10-fold less, or
about 8-fold
less, or about 5-fold less, or about 3-fold less, about 2-fold less or about
1.5-fold less than
the standard daily dosage, e.g. than the therapeutic dose. Suitably the
initial dosage
administered during the initial period of treatment is about 10-fold less than
the standard
daily dosage, e.g. than the therapeutic dose, and is then increased in
increments to a daily
dosage which is about 5 fold less than the standard daily dosage and then
about 2.5 fold
less than the standard daily dosage. Thereafter, treatment is commenced at the
standard
daily dosage.
In another embodiment of the invention, the initial dosage administered during
the initial
period of treatment as hereinabove defined is about 4-fold less than the
standard daily
dosage, e.g. than the therapeutic dose, and is then increased in increments to
a daily
dosage which is about 2 fold less than the standard daily dosage. Thereafter,
treatment is
commenced at the standard daily dosage.
The same dose may be given during the first 1, 2, 3, 4, 5, 6, 7 or 8 days of
treatment before
the dosage is increased, preferably during the first 2 to 4 days of treatment.
Suitably each
subsequent incremental dosage increase is administered for 1, 2, 3, 4 or 5
days. In a
CA 02747802 2011-06-20
WO 2010/075239 PCT/US2009/068888
- 11 -
particular embodiment, each subsequent incremental dosage increase is
administered for 2
or 3 days.
During the initial period of treatment, i.e. before the standard daily dosage
is given, the same
initial dosage may be given during the first 1 to 7 days, e.g. for 2 to 5
days, e.g. the first 2
days, before the dosage is further increased, e.g. up to the standard daily
dosage in one or
more increments.
One or more dosage increases, e.g. up to 10 dosage increases, e.g. up to 8
dosage
increases, e.g. up to 6 dosage increases, e.g. up to 5 dosage increases, up to
4 dosage
increases, up to 3 dosage increases, may be performed until the standard daily
dosage is
given. For example 1 to 10, e.g. 1 to 8, e.g. 1 to 3, e_g. 2 to 8, e.g. 3 to 6
dosage increases
may be given.
In an embodiment, the daily dosage is governed by a Fibonacci series i.e. the
dosage given
on a specific day is the sum of the dosages on the previous two days. In an
aspect of this
embodiment, some variation in this scheme is permitted. For example, the
dosage on a
given day may be the sum of the dosages on the two previous days 40%, for
example
30%, for example 20% or 10%.
For example, the first dosage increase may occur on day 2 to day 5, e.g. day 2
to day 4, e.g.
day 2, day 3, day 4 or day 5, after the first administration. The second
dosage increase, if
any, may occur on day 4 to 10, e.g. day 4 to 6, e.g. day 5, after the first
administration. The
third dosage increase, if any, may occur on day 6 to 10, e.g. day 6 or 7,
after first
administration.
In one embodiment of the invention, only one or two dosage increase occur
before the
standard daily dosage, e.g. the therapeutic dosage, is given.
In a particular embodiment, the SIP receptor agonist is Compound A or Compound
B, e.g.
F1Y720, or a pharmaceutically acceptable salt thereof, e.g. the hydrochloride
salt of
FTY720.
According to a preferred embodiment of the invention, the highest initial
dosage of the SIP
receptor modulator or agonist (e.g. Compound A, Compound B or a salt thereof)
is between
0.01 mg and 0.30 mg, e.g. between 0.125 and 0.25mg, preferably 0.125mg or
0.1mg.
A particularly preferred dosage range of the SIP receptor modulator or agonist
(e.g.
Compound A,Compound B or a salt thereof, e.g. the hydrochloride salt of
FTY720) during
the initial period of treatment as hereinabove defined is e.g. 0.125-1.25 mg,
or 0.1-0.5 mg,
or 0.125-0.5 mg, or 0.25-0.5 mg.
CA 02747802 2011-06-20
WO 2010/075239 PCT/US2009/068888
- 12 -
For example it may be a regimen of 0.125mg/0.25mg/0.5mg, respectively, during
the initial
period of e.g. up to the first 10 days. Thereafter the treatment is continued
with the standard
daily dosage, e.g. a dosage of 1.25 mg. This regimen is particularly adapted
for compound
A.
Alternatively, it may be a regimen comprising an initial daily dose of 0.125mg
which is
subsequently increased to a daily dose of 0.25mg during the initial period of
treatment.
Thereafter the treatment is continued with the standard daily dosage, e.g.
0.5mg. Again, this
regimen is particularly adapted for compound A.
In a series of further specific or alternative embodiments, the present
invention also
provides:
1.1 The use of a SIP receptor modulator or agonist which induces a negative
chronotropic effect in heart rate, e.g. compound A, or B, or a salt or prodrug
thereof,
preferably compound A, a salt or prodrug thereof, in the manufacture of a
medication,
whereby said medication is administered in such a way to a subject that the
daily
decrease in heart rate (e.g. the average daily heart rate) is approximatively
of 2
beats/min or less.
1.2 The use of a SIP receptor modulator or agonist, e.g. compound A, or B,
or a salt or
prodrug thereof, preferably compound A, a salt or prodrug thereof, in the
manufacture of a medication, whereby said medication is administered in such a
way
to a subject that at the day the therapeutic dosage of said SIP receptor
modulator or
agonist is administered the decrease in heart rate (e.g. the average daily
heart rate)
is approximatively of 2 beats/min or less.
1.3 The use of a SIP receptor modulator or agonist, e.g. compound A, or B,
or a salt or
prodrug thereof, preferably compound A, a salt or prodrug thereof, in the
manufacture of a medication, whereby said medication is administered at a
lower
dosage than standard dosage, e.g. up to 10-fold less, e.g. 4-fold less, than
the
standard daily dosage, during the initial period, e.g. during the first 10
days of
treatment or during the first week of treatment. Optionally the dosage is then
increased stepwise up to the standard daily dosage, e.g. the therapeutic
dosage, of
said S1P receptor agonist.
During the initial period of treatment, e.g. the initial 10 days, e.g. 9 days,
e.g. a the first
week, of treatment, the daily dosage of the S1P receptor modulator or agonist
is lower than
the standard dosage, and is raised stepwise up to 6 times, e.g. three times,
e.g. two
times,up to the standard daily dosage of said S1P receptor modulator or
agonist and
CA 02747802 2011-06-20
WO 2010/075239
PCT/US2009/068888
- 13 -
thereafter the treatment is continued with the standard daily dosage of said
SIP receptor
modulator or agonist.
1.4. The use of a SIP receptor modulator or agonist, e.g. compound A, or B,
or a salt or
prodrug thereof, preferably compound A, a salt or prodrug thereof, in the
manufacture of a medication, whereby said medication is administered in such a
way
that during the initial period of treatment, e.g. the initial 10 days of
treatment, e.g. the
initial first week of treatment, the dosage of said S1P receptor modulator or
agonist is
10; 5; and 2-3 fold less than the standard daily dosage, respectively, and
thereafter
the treatment is continued with the standard daily dosage of the SIP receptor
modulator or agonist.
1.5 The use of a S1P receptor modulator or agonist, e.g. compound A, or B,
or a salt or
prodrug thereof, preferably compound A, a salt or prodrug thereof, in the
manufacture of a medication, whereby said medication is administered in such a
way
that during the initial period of treatment, e.g. the initial 10 days of
treatment, e.g. the
initial first week of treatment, the dosage of said SIP receptor modulator or
agonist is
4; and 2 fold less than the standard daily dosage, respectively, and
thereafter the
treatment is continued with the standard daily dosage of the SIP receptor
modulator
or agonist.
1.6 The use of a SIP receptor modulator or agonist, e.g. compound A, or B,
or a salt or
prodrug thereof, preferably compound A, a salt or prodrug thereof, in the
manufacture of a medication, whereby said medication is administered in such a
way
that during the initial period of treatment, e.g. the initial 10 days of
treatment, e.g. the
initial first week of treatment, the dosage of said SIP receptor modulator or
agonist
increases from an initial dosage which is 10 fold less than the standard daily
dosage
to a dosage which is 1.5-3 or 2-3 fold less than the standard daily dosage,
and
thereafter the treatment is continued with the standard daily dosage of the
S1P
receptor modulator or agonist.
1.7. The use of a S1P receptor modulator or agonist, e.g. compound A, 13,
or a salt or
prodrug thereof, preferably compound A, or a salt or prodrug thereof, in the
manufacture of a medication, whereby said medication is administered in such a
way
that during the initial 2 to 4 days of treatment the dosage of said SIP
receptor
modulator or agonist is not more than 1/10, or not more than 1/4, of the
standard daily
dose of the SIP receptor modulator or agonist.
CA 02747802 2011-06-20
WO 2010/075239 PCT/US2009/068888
- 14 -
1.8 The use of a SIP receptor modulator or agonist, e.g. compound A, B, or
a salt or
prodrug thereof, preferably compound A, or a salt or prodrug thereof, in the
manufacture of a medication, whereby said medication is administered in such a
way
that during the initial 2 to 4 days of treatment the dosage of said S1P
receptor
modulator or agonist is not more than 10% or not more than 25% of the standard
daily dose of the S1P receptor modulator or agonist.
1.9 The use of an S1P receptor modulator or agonist, e.g. compound A, B, or
a salt or
prodrug thereof, in the manufacture of a medication, whereby said medication
is
administered in such a way that during the initial 10 days, e.g. 9 days, of
treatment
the dosage of said S1 P receptor modulator or agonist is lower than the
standard daily
dosage of said S1 P receptor modulator or agonist and then the dosage is
raised so
that the standard daily dosage is administered after several dose increases,
up to 10,
e.g. up to 6, e.g. two or three dose increases, and thereafter the treatment
is
continued with the standard daily dosage of said SIP receptor agonist.
1.10 The use of a S1P receptor modulator or agonist, e.g. compound A, or B, or
a salt or
prodrug thereof, preferably compound A, a salt or prodrug thereof, in the
manufacture of a medication, whereby said medication is administered in such a
way
to a subject that the possible risk of AV block is limited or reduced to a
level clinically
not significant. Preferably the use is then as defined under 1.1 to 1.9.
1.11 The use of a SIP receptor modulator or agonist, e.g. compound A, or B, or
a salt or
prodrug thereof, preferably compound A, a salt or prodrug thereof, in the
manufacture of a medication, whereby said medication is administered in such a
way
to a subject that the sinus rhythm of the patient is normal. Preferably the
use is then
as defined under 1.1 to 1.9.
1.12 Use as defined under 1.1 to 1.11, wherein the initial period of treatment
is of up to 10
days, e.g. up to 8 days , e.g. a week.
1.13 The use as defined under 1.1 to 1.12 wherein the medication is given to a
patient
who is at risk of heart failure.
1.14 The use as defined under 1.1 to 1.12 wherein the medication is given to a
patient
who is at risk of AV block.
1.15 The use as defined under 1.1 to 1.12 wherein the medication is given to a
patient
who experience symptoms including dizziness, fatigue, palpitations.
CA 02747802 2011-06-20
WO 2010/075239 PCT/US2009/068888
- 15 -
1.16 The use as defined under 1.1 to 1.12 wherein the medication is given to a
patient with
high grade atrio-ventricular blocks or sick sinus syndrome.
1.17 The use as defined under 1.1 to 1.12 wherein the medication is given to a
patient with
arrhythmias, e.g. requiring or under treatment with Class la (e.g. quinidine,
procainamide) or Class III anti-arrhythmic drugs (e.g. amiodarone, sotalol).
1.18 The use as defined under 1.1 to 1.12 wherein the medication is given to a
patient
requiring or under beta-blocker therapy.
1.19 The use as defined under 1.1 to 1.18 wherein the medication is given to a
patient,
e.g. a patient suffering from multiple sclerosis, wherein the administration
of said S1P
receptor modulator or agonist, e.g. compound A, or B, or a salt or prodrug
thereof,
preferably compound A, a salt or prodrug thereof, has been discontinuedformore
than
days, e.g. more than 12 days, e.g. more than 14 days.
1.20 The use of FTY720, a salt or prodrug thereof in the manufacture of a
medication,
whereby said medication is administered, after an initial regimen as
hereinabove
defined, at a daily dosage of about 1.25 mg, or about 0,5mg or less as herein
above
defined.
1.21 Use as defined in 1.1 to 1.20, for treating a chronic long term diseases,
such as an
autoimmune disease, e.g. multiple sclerosis, e.g. RRMS.
1.22 Use of FTY720 (Compound A), Compound B, or a pharmaceutically acceptable
salt
thereof, in the manufacture of a medicament for use in the treatment of
autoimmune
diseases, wherein, prior to commencing the administration of FTY720, Compound
B,
or a pharmaceutically acceptable salts thereof, at the standard daily dosage,
the
FTY720, Compound B, or a pharmaceutically acceptable salts thereof, is
administered at a daily dosage which is lower than the standard daily dosage
during
an initial period of treatment as herein above defined (e.g. up to 10 days).
1.23 The use as defined in 1.22 wherein the standard daily dosage is about
0.5mg to
about 1.25mg.
1.24 The use as defined in 1.23 wherein an initial daily dose of 0.125 mg is
administered
which is subsequently increased to 0.25 mg and then further increased to 0.5
mg
during the initial period of treatment, and thereafter treatment is continued
at the
standard daily dosage, e.g. 1.25 mg.
CA 02747802 2011-06-20
WO 2010/075239
PCT/US2009/068888
- 16 -
1.25 The use as defined in 1.23 wherein an initial daily dose of 0.125 mg is
administered
which is subsequently increased to 0.25 mg during the initial period of
treatment and
thereafter treatment is continued with the standard daily dosage, e.g. 0.5 mg.
In a treatment method with a SIP receptor modulator or agonist, e.g. compound
A, B or a
salt or prodrug thereof, the improvement is due to said S1P receptor modulator
or agonist is
administered in such a way that during the initial period of treatment, e.g.
the initial 10 days,
e.g. 9 days, e.g. first week, of treatment, the dosage is lower than the
standard dosage, e.g.
10-fold less, e.g. 5-fold less, e.g. 4 fold-less, e.g. 2 to 3 fold-less, e.g.
2 fold-less, than the
standard daily dosage, and is increased, optionally stepwise, up to the
standard daily
dosage. Thereafter the treatment is continued with the standard effective
daily dosage.
Furthermore there is provided:
2.1 A method for treating a patient in need thereof such a method
comprising
administering a SIP receptor modulator or agonist which induces a negative
chronotropic effect in heart rate, e.g. compound A, B, or a salt or prodrug
thereof,
comprising administering to the subject a S1P receptor modulator or agonist in
such a
way that at the day the therapeutic dosage is administered the decrease in
heart rate
(e.g. the average daily heart rate) is clinically not significant, preferably
is limited to
approximatively 2 beats/min or less.
2.2 A method as defined under 2.1 comprising administering to the subject
sub-
therapeutic doses of the SIP receptor agonist during the initial period of
treatment.
2.3 A method for treating a chronic long term diseases as herein above
defined, e.g. an
autoimmune disease, e.g. multiple sclerosis, e.g. RRMS, in a subject in need
thereof,
comprising administering to the subject, a loading regimen of a SIP receptor
modulator or agonist, e.g. compound A, B, or a salt or prodrug thereof, at a
daily
dosage which is lower than the standard daily dosage.
2.4 A method for treating a chronic long term diseases as herein above
defined, e.g. an
autoimmune disease, e.g. multiple sclerosis, e.g. RRMS, in a subject in need
thereof,
comprising administering to the subject, a S1 P receptor modulator or agonist,
e.g.
compound A, B, or a salt or prodrug thereof, at a daily dosage which is lower
than the
standard daily dosage and raising the daily dosage stepwise up to the standard
daily
dosage during the initial period of treatment, e.g. the first 10 days.
2.5 A method for treating a chronic long term diseases as herein above
defined, e.g. an
autoimmune disease, e.g. multiple sclerosis, e.g. RRMS, in a subject in need
thereof,
comprising administering to the subject, an initial regimen up to 10-fold less
the
CA 02747802 2011-06-20
WO 2010/075239 PCT/US2009/068888
- 17 -
standard daily dosage, and thereafter the daily dosage of a Si P receptor
modulator or
agonist, e.g. compound A, B, or a salt or prodrug thereof.
2.6 A method of ameliorating or preventing a negative chronotrophic side
effect associated
with a treatment using an SIP modulator or agonist, e.g. compound A, B, or a
salt or
prodrug thereof, of a subject suffering from an autoimmune disease, comprising
administering to the subject in need thereof, said S1P receptor modulator or
agonist at
a daily dosage which is lower than the standard daily dosage during an initial
treatment
period and raising the daily dosage stepwise up to the standard daily dosage.
2.7 A method as defined under 2.1 to 2.6 whereby the initial period of
treatment is of up to
days, e.g. up to 8 days , e.g. a week.
2.8 A method as defined under 2.1 to 2.6 wherein the initial treatment
period is 6-14 days
e.g. 7-10 days e.g. 7 days or less, as herein above described.
2.9. A method as defined under 2.1 or 2.8 for treating an autoimmune disease,
e.g. multiple
sclerosis.
2.10 The method as defined in 2.1 to 2.9, wherein the SIP receptor modulator
or agonist, is
FTY720 or a pharmaceutically acceptable salt thereof, e.g. hydrochloride salt,
or
FTY720 phosphate, and is administered, after an initial regimen, at a daily
dosage of
about 1.25 mg, or about 0,5mg or less as herein above defined.
2.11 A method of treating a chronic long term diseases as herein above
defined, e.g. an
autoimmune disease, e.g. multiple sclerosis, e.g. RRMS, in a patient in need
of such
treatment, the method comprising initialing treatment with the S1P receptor
modulator
or agonist at a daily dosage which is lower than the standard daily
therapeutic dosage
during an initial period of treatment and thereafter commencing the
administration of
the S1P receptor modulator or agonist at the required standard daily
therapeutic
dosage.
2.12 A method of ameliorating or preventing a negative chronotrophic side
effect associated
with a treatment of an autoimmune disease using an S1P modulator or agonist,
e.g.
compound A, B, or a salt or prodrug thereof, the method comprising
administering the
S1 P receptor modulator or agonist at a daily dosage which is lower than the
standard
daily dosage during an initial treatment period and raising the daily dosage,
optionally
stepwise, up to the standard daily dosage.
2.13 A method of treating a chronic long term diseases as herein above
defined, e.g. an
autoimmune disease, e.g. multiple sclerosis, e.g. RRMS, in a patient who is at
risk of
CA 02747802 2011-06-20
WO 2010/075239 PCT/US2009/068888
- 18 -
heart failure, the method comprising administering the S1P receptor modulator
or
agonist, e.g. compound A, B, or a salt or prodrug thereof.
2.14 A method of treating a chronic long term diseases as herein above
defined, e.g. an
autoimmune disease, e.g. multiple sclerosis, e.g. RRMS, in a patient who is at
risk of
AV block, with high grade atria-ventricular blocks or sick sinus syndrome, the
method
comprising administering the S1P receptor modulator or agonist, e.g. compound
A,
B, or a salt or prodrug thereof.
2.15 A method of treating a chronic long term diseases as herein above
defined, e.g. an
autoimmune disease, e.g. multiple sclerosis, e.g. RRMS, in a patient who
experiences symptoms including dizziness, fatigue, palpitations, the method
comprising administering the S1P receptor modulator or agonist, e.g. compound
A,
B, or a salt or prodrug thereof.
2.16 A method of treating a chronic long term diseases as herein above
defined, e.g. an
autoimmune disease, e.g. multiple sclerosis, e.g. RRMS, in a patient with
arrhythmias, e.g. requiring or under treatment with Class la (e.g. quinidine,
procainamide) or Class III anti-arrhythmic drugs (e.g. amiodarone, sotalol);
or in a
patient requiring or under beta-blocker therapy, the method comprising
administering
the S1P receptor modulator or agonist, e.g. compound A, B, or a salt or
prodrug
thereof.
2.17 A method of treating a chronic long term diseases as herein above
defined, e.g. an
autoimmune disease, e.g. multiple sclerosis, e.g. RRMS, while limiting the
occurrence
of symptoms including dizziness, fatigue, heart palpitations, the method
comprising
administering the SIP receptor modulator or agonist, e.g. compound A, B, or a
salt or
prodrug thereof.
2.18 A method as defined in 2.11 or 2.17 wherein the SIP receptor modulator or
agonist is
selected from Compound A (FTY720), or a pharmaceutically acceptable salt
thereof,
and FTY720 Phosphate (Compound B), or pharmaceutically acceptable salts
thereof.
In yet another embodiment of the invention, there is provided
3,0 A Si P receptor modulator or agonist for use in the treatment of a
chronic long term
diseases as herein above defined, e.g. an autoimmune disease, e.g. multiple
sclerosis,
e.g. RRMS, wherein, prior to commencing the administration of the SIP receptor
modulator or agonist at the standard daily therapeutic dosage, said SIP
receptor
CA 02747802 2011-06-20
WO 2010/075239 PCT/US2009/068888
- 19 -
modulator or agonist is administered at a daily dosage which is lower than the
standard
daily therapeutic dosage during an initial period of treatment.
4.0 A kit containing daily units of medication of an S1P receptor modulator
or agonist, e.g.
compound A, B, or a salt or prodrug thereof, of varying daily dosage, whereby
said
doses are lower than the standard daily dosage.
41 A kit comprising units of medication of a SIP receptor modulator or
agonist as defined
herein for administration according to the dosage regimen defined herein,
whereby one
or more low-dose units of a dose strength below the standard daily dose of the
SIP
receptor agonist are provided for the initial period of treatment as herein
above
defined, e.g. the frst week of treatment.
4.2 A kit containing units of medication of an S1P receptor modulator or
agonist as defined
herein of varying daily dosage, whereby said kit contains a) at least one of
the
following : about 1/10, about 1/8, about 1/5, about %, about 1/3, about 1/2.5,
about 1/2,
about 1/1.5, of the standard dose of the SIP receptor modulator or agonist,
respectively, and b) optionally units for the standard daily dosage of the S1P
receptor
modulator or agonist.
In an embodiment, the kit may comprise just one low dose unit of medication at
a dosage
strength corresponding to an initial dosage of the SIP receptor modulator or
agonist. A
patient may then take one unit of the low dose medication for a specified
number of days
and then, optionally, two or more units per day on subsequent days until
therapy is
commenced with a unit of medication that comprises the standard daily dose of
the SIP
receptor agonist.
In an alternative embodiment, the kit may comprise a number of low-dose units
of
medication with a range of dosage strengths so that the patient can be
administered one
dosage unit per day, but the amount of SIP receptor modulator or agonist
administered can
be titrated upwards until therapy commences at the standard daily dosage.
For example, the daily units of said S1P receptor modulator or agonist may be
of about 1/10,
about 1/5 and about 1/2.5; or about 1/5 and about 1/2.5, of the standard dose
of said SIP
receptor modulator or agonist, respectively.
In another embodiment, the daily units of said S1P receptor modulator or
agonist may be of
about 1/8, about 1/4 and about 1/2; or about 1/4 and about 1/2, of the
standard dose of said
S1P receptor modulator or agonist, respectively.
CA 02747802 2011-06-20
WO 2010/075239 PCT/US2009/068888
- 20 -
The kit may further comprise units for the standard daily dosage of the S1P
receptor
modulator or agonist, e.g. compound A, B, or a salt or prodrug thereof.
The kit may also contain instructions for use.
in yet another embodiment of the invention, there is provided
5.1 A method for treating a chronic long term diseases as herein above
defined, e.g. an
autoimmune disease, e.g. multiple sclerosis, e.g. RRMSõ or a method for
treating an
autoimmune disease in a subject in need thereof in a subject in need thereof,
comprising administering to the subject, a daily dosage of FTY720 or a
pharmaceutically acceptable salt thereof, e.g. of about 1.25 mg, or about
0,5mg or
less as herein above defined.
5.2. The method as defined in 5.1, wherein the disease is multiple sclerosis,
e.g. RRMS.
5.3. The method as defined in 5.1, wherein the autoimmune disease is
multiple sclerosis.
6.1 A method for assessing the need or suitability of a patient for a
treatment regimen as
described above (e.g. in any of the specified aspects or embodiments of the
invention), comprising the steps of:
(i) determining whether the patient to be treated with an SIP receptor
modulator or
agonist is in a category for which the use of a treatment regimen as described
above
may be beneficial; and
(ii) if the patient falls within this category, treating the patient using a
treatment
regimen as described above.
6.2 The method as defined in 6.1 wherein the patient may be in the above
category if he
or she suffers from or is susceptible to heart failure, arrhythmias, high
grade atrio-
ventricular blocks or sick sinus syndrome or has a history of syncopal
episodes; or is
undergoing beta blocker or anti-arrhythmic treatment, e.g. is under treatment
with
anti-arrhythmic drugs; or has undergone an interruption or treatment holiday
in the
maintenance dosage regime e.g. a holiday of greater than 4 days, greater than
6, 8,
10, 12 or 14 days.
The regimen of SIP receptor modulator or agonist which is administered to the
subject
according to the invention may be given either during at the beginning of the
disease
therapy, e.g. during the initial 10 days, or after an interruption of S1P
receptor modulator or
CA 02747802 2011-06-20
WO 2010/075239
PCT/US2009/068888
- 21 -
agonist therapy, for example an interruption of more than 10 days, more than
12 days, e.g.
more than 14 days.
In a further aspect, the present invention relates to a daily dosage of the
S1P receptor
modulator or agonist, e.g. compound A (or B), or, in each case, a
pharmaceutically
acceptable salt, e.g. a hydrochloride salt, thereof, is selected from any one
of the following:
about 1.25 mg or less, e.g. is from about 1.25 mg to about. 0.01 mg, e.g. is
1.25 mg, e.g.
1.20 mg, e.g. 1.15 mg, e.g. 1.10 mg, e.g. 1.05mg, e.g. 1.00 mg, e.g. 0.95mg,
e.g. 0.90 mg,
e.g. 0.85mg, e.g. 0.80 mg, e.g. 0.75 mg, e.g. 0.70 mg, e.g. 0.65 mg, e.g. 0.60
mg. e.g. 0.55
mg, e.g. 0.50 mg, e.g. 0.45 mg, e.g. 0.40 mg, e.g. 0.35 mg, e.g. 0.30 mg, e.g.
0.25mg, e.g.
0.20 mg, e.g. 0.15 mg, eig. 0.125 mg, e.g. 0.12 mg, e.g. 0.115 mg, e.g.
0.11mg, e.g. 105
mg, e.g. 0.1 mg, e.g. 0.055 mg, e.g. 0.05 mg, e.g. 0.045 mg, e.g. 0.04 mg.
e.g. 0.035 mg,
e.g. 0.03 mg, e.g. 0.025 mg, e.g. 0.02 mg, e.g. 0.01 mg.
Preferably the daily dosage of the compound, e.g. FTY720 or FTY720 phosphate,
is 0.5mg.
The present invention therefore includes, in a further aspect, the above
mentioned daily
dosages of FTY720, FTY720 phosphate or, in each case, a pharmaceutically
acceptable
salt, e.g. a hydrochloride salt, thereof. In particular, the invention relates
to the above
mentioned daily dosages of FTY720 phosphate or the hydrochloride salt of
FTY720.
In a specific embodiment the daily dosage of FTY720, FTY720 phosphate or, in
each case,
a pharmaceutically acceptable salt, e.g. a hydrochloride salt, is about 0.5
mg, or about
0.25mg, or about 0.125 mg, or about 0.1mg.. In another embodiment the daily
dosage of
FTY720 phosphate or the hydrochloride salt of FTY720 is about 0.5 mg, or about
0.25mg, or
about 0.125 mg, or about 0.1mg.
The utility of an S1P receptor modulator or agonist dosage regimen in treating
diseases and
conditions as hereinabove specified may be demonstrated in standard animal or
clinical
tests, e.g. in accordance with the methods described hereinafter.
Brief description of the Figure:
Figure 1 shows the mean (+/- standard error) daily average heart rate on days
1 to 9 for the
treatment regimen groups described in the Example below. The x-axis is shows
the study
days and the Y-axis shows the mean (+/-SE) daily average heart rate (beats per
minute
(BPM)).
CA 02747802 2011-06-20
WO 2010/075239 PCT/US2009/068888
- 22 -
Example:
A single-center, double-blind, placebo-controlled, dose titration, once-daily,
multiple-
oral-dose clinical study in healthy subjects was conducted to evaluate the
effect of a
dosage regimen of FTY720 according to the present invention.
A total of 36 subjects were randomly assigned to one of the three groups.
Each subject participated in a screening period of maximal 21 days, a baseline
period (Day -1), a 9-day dose-administration period, and clinical study
completion
assessments on Day 10. Subjects were assigned to one of the three groups (dose
titration regimen group, placebo control group, or active control group) and
received
the once daily dose in a double-blinded manner (Table 1).
In the dose titration group, increasing once daily doses of Compound A
(FTY720),
starting at 0.125 mg o.d. and ending at the maximal therapeutic dose of 1.25
mg o.d.
were administered on days 1 to 9 of the study according to the schedule shown
in
Table 1 below. The placebo control group received placebo through out the
duration
of the study and the active control group received a once daily dose of 1.25
mg of
FTY720 on days 1 to 9.
Table 1
Study Baseline Administration period
group
Number of
subjects
Day Day -1 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9
Dose Placebo 0.125 0.125 0.125 0.25 0.25 0.5 mg
0.5 mg 1.25 1.25 mg
titration mg mg mg mg mg mg
regimen
group!
N = 15
Placebo Placebo Placebo, once daily over 9 days
control
group!
N = 9
Active Placebo 1.25 mg, once daily over 9 days
control
group /
N = 12
On Day -1 (baseline), subjects will undergo baseline assessments including 24
hour
holter monitoring and telemetry assessments.
CA 02747802 2011-06-20
WO 2010/075239 PCT/US2009/068888
- 23 -
Pharmacodynamic and safety assessments are performed up to 24 hours post last
dose. Heart rate is monitored via telemetry on Day -1 through Day 10, 24 hour
after
the last dosing. Heart rhythm is assessed via 24hr continuous bolter
monitoring on
Day -1, Day 1, and Day 9. For each dosing for each subject, the drug is
administered
as closely as practically possible to the time administered on Day -1. Safety
assessments includes physical examinations, vital signs and body measurements,
12-lead ECG evaluations, standard clinical laboratory evaluations hematology,
blood
chemistry, urinalysis, adverse event and serious adverse event monitoring.
Systolic
and diastolic blood pressure and pulse are measured after the subject has
rested
quietly in the sitting position for at least 3 minutes. Blood pressure is
measured at the
same arm on each occasion. Standard 12-lead ECGs are recorded at Screening,
baseline, 4 hours post-dose on Day 1 and Day 8, and at Study Completion. The
variables recorded are: date and time of ECG, heart rate, PR interval, QT
interval
(uncorrected), QTcB, QRS duration. The overall interpretation is collected
with a
Yes/No statement to confirm if any clinically relevant abnormalities are
present,
which needs to be specified further.
Subjects remain on continuous telemetry, starting before breakfast on Day -1
and
proceeding throughout the administration period up to Day 10 (24 hour after
the last
dose). Over this ten day duration of continuous heart rate collection for each
subject,
one heart rate value is obtained every minute ('minute unit heart rate'),
representing
the average heart rate value over that minute. The heart rate database for
each
subject contains approximately 14,400 data points (10 days x 24 hr x 60 min).
24-hour continuous Holter-ECG data are captured via a digital Hotter monitor
(12-
lead, on Days -1, 1, 6, and 8), and transferred for interpretation and
reporting. Holter
monitoring starts approximately at 7:00 and the time of dose administration is
regarded as the time "0 hours". Hotter "cuts" are derived from the dataset at
1 hour
intervals starting from Day -1 and continuing for 24 hours or the end of the
cleaned
Ho!ter monitoring dataset.
Cardiac conduction intervals: arrhythmia monitoring includes the frequency and
duration of sinus pauses (>2 sec and > 3 sec) and atrio-ventricular blocks.
Frequency and duration of atrial and ventricular ectopy and sinus rhythm are
also
recorded.
The daily chronotropic effect is defined as the percent decrease in HRmin
(minimum heart
rate) between two consecutive days. It is calculated on days 1 to 9.
Results:
CA 02747802 2011-06-20
WO 2010/075239 PCT/US2009/068888
- 24 -
The results are shown in Figure 1. in the placebo group, daily average heart
rate
varies by approximately 5 BPM (beats per min) over the course of the study
with a
trend for heart rate to increase approximately 3-4 BPM from Day -Ito Day 2.
The
F1Y720 1.25 mg treatment group manifestes a significant decrease in heart rate
of
approximately 8 BPM from Day -Ito Day 1 and an additional decrease in heart
rate
approximately 3 BPM from Day 1 to Day 2. The FTY720 titration group manifestes
a
gradual decrease in heart rate of approximately 1-2 BPM per day over the
course of
eight day course of the dose titration. The initiation of the 1.25 mg FTY720
on Day 8
does not result in dip in heart rate compared to the preceding days.
These results indicate that the use of a dose titration regimen according to
the invention
attenuates the negative chronotropic effect seen on Day 1 of F1Y720 treatment
initiation.
Furthermore multiple analyses have been conducted to compare minimum heart
rates
between the two FTY720 treatment group. These analysis show that the FTY720
dose
titration regimen provides improved daily minimum heart rates during the
course of the
study.
